For instance, in a HFD-mediated NAFLD rat model, simvastatin was found to protect against the development of HFD-induced liver fibrosis via differentially regulating NOS isozymes, where eNOS was found to be elevated while iNOS was decreased [112]. This evidence concerns the gene NOS2 and metabolic dysfunction-associated steatotic liver disease.